PTC Therapeutics Boosts Workforce with Stock Options and RSUs for New Employees

PTC Therapeutics Expands Workforce with Strategic Stock Options and RSUs for New Hires

PTC Therapeutics, Inc. announces a strategic initiative to enhance its workforce by granting stock options and restricted stock units (RSUs) to 15 new employees. This development, dated December 1, 2025, reflects the company's commitment to attracting top talent in the biopharmaceutical industry, particularly those focused on innovative treatments for rare disorders. The company's Compensation Committee approved non-statutory stock options allowing the purchase of 2,000 shares and 8,200 RSUs, designed to incentivize these new hires to join the organization. Such initiatives not only align with PTC's growth strategy but also comply with Nasdaq Listing Rule 5635(c)(4), ensuring transparency and adherence to regulatory standards.

The stock options come with an exercise price of $79.83 per share, matching the closing price on the grant date. This unique approach to compensation allows PTC to align employee interests with company performance, promoting a culture of ownership and accountability. The options are structured with a 10-year term and vesting schedule that spans four years, with an initial 25% vesting upon the first anniversary of each employee's start date, followed by incremental vesting every three months. By establishing a clear and rewarding path for new hires, PTC Therapeutics demonstrates its commitment to fostering employee engagement and retention, crucial for maintaining momentum in the competitive biopharmaceutical landscape.

In addition to the stock options, the RSUs granted to new employees also follow a four-year vesting schedule, with 25% vesting annually on the anniversary of the hire date. This structured vesting not only encourages long-term commitment among employees but also aligns their success with the company's objectives, reinforcing PTC's mission to develop and commercialize transformative therapies. As a global biopharmaceutical leader, PTC Therapeutics focuses on addressing unmet medical needs, leveraging its scientific expertise to deliver innovative solutions for patients with rare disorders.

In a broader context, PTC Therapeutics continues to enhance its reputation as a pioneer in the biopharmaceutical industry. As the company expands its workforce, it exemplifies a proactive approach to talent acquisition, essential for driving innovation and maintaining its competitive edge. Interested stakeholders can learn more about PTC's initiatives and ongoing projects through their official website and social media channels.